ncRNA basic information
ncRNA ID:
MI0000103/MI0000739
ncRNA Database:
miRBase
ncRNA Name:
miR-101
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
qRT-PCR
ncRNA Target Gene:
ANXA2
ncRNA Pathway:
p38MAPK and AKT pathways
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00515 (APRD00359)
Drug Name:
Cisplatin
Drug Method:
The expressions of miR-101 and Annexin A2 (ANXA2) in GC tissues and cells were detected by qRT-PCR and western blot. The effects of miR-101 overexpression on P-glycoprotein (P-gp) at mRNA and protein levels, cell viability, and apoptosis in drug-resistant GC cells were examined by qRT-PCR, western blot, MTT and flow cytometry analysis, respectively. Luciferase reporter assay, RNA immunoprecipitation (RIP) and qRT-PCR were applied to confirm whether miR-101 could target ANXA2 and regulate its expression. Rescue experiment was performed to verify the mechanism by which miR-101 involved in chemoresistance.
Drug Response:
sensitive
Cancer basic information
Cancer:
stomach cancer
Tissue/Cell:
tissue and cell line (SGC7901,SGC7901/DDP,SGC7901/VCR)
Other information
Title:
miR-101 alleviates chemoresistance of gastric cancer cells by targeting ANXA2.
Journal:
Biomed Pharmacother
Published:
2017
PubMed ID:
28609840